E. Transcriptome profile changes mediated by the synergy of TP-16 and anti-PD-1 analyzed using Agilent SurePrint G3 Mouse GE V2.0 Microarray. Venn diagrams depicting the number of changed genes (FC ≥ 2 or FC ≤ −2, P ≤ 0.05) compared with vehicle control following TP-16, anti-PD-1 antibody, or TP-16 and anti-PD-1 combined therapy. 